HCM LSE Week ended 07 Aug 2026

Weekly Investor Report

HUTCHMED (China) Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 184.0 GBP
8.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -5.5% below the Trend Line and sits at 28.4% of its 52-week range. The latest completed week returned 8.2%, after a 11.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is inexpensive relative to peers. The latest news-sentiment score is 53/100.

Setup score 40 out of 100
Latest Close 184.0 GBP 7 Aug 2026
1W Return 8.2% latest completed week
4W Return 11.5% short-term follow-through
12W Return -0.5% quarterly tape
Trend Breadth 17.3% 9 of 52 weeks active
Volume Ratio 2.7x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.2% Latest completed week; four-week move 11.5%. Indicator stack 10/58 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 53/100 15 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -5.5% below the Trend Line and sits at 28.4% of its 52-week range. The latest completed week returned 8.2%, after a 11.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 11.5% over four weeks, -0.5% over 12 weeks, and -18.0% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.2%
4W11.5%
12W-0.5%
26W-14.0%
52W-18.0%
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.00Latest activity-pressure read.
Pressure change99.6%Four-week change in activity pressure.
Leadership-18.80Latest relative-leadership reading.
RS change31.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 65%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength40/100Blend of value, momentum, and quality. Underlying universe rank 61; rank 1 is best.
Value86/100Relative valuation strength. Underlying universe rank 15; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum5/100Medium-term price momentum. Underlying universe rank 96; rank 1 is best.
Growth8/100Revenue and earnings growth. Underlying universe rank 93; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
3.5x
Price divided by trailing earnings.
Price / sales
2.9x
Market value relative to trailing revenue.
EV / EBITDA
3.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-5.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
38.7%
Gross profit retained from each unit of revenue.
Operating margin
-6.5%
Operating profit retained from revenue.
Free-cash-flow margin
-16.2%
Free cash flow generated from revenue.
Return on invested capital
-2.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-13.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.1%
Net share repurchases relative to market value.
Shareholder yield
-0.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 15 relevant articles.

3 positive · 12 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-30.8%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2614 weeks finished lower.
Best week+11.2%Week of 3 Jul.
Worst week-8.6%Week of 24 Apr.
Latest week+8.2%Week of 7 Aug.

Shape of recent returns

Strong gains4
Modest gains6
Flat weeks2
Modest losses9
Sharp losses5
Recent vol5.8%13-week weekly-return volatility.
Base vol5.3%52-week weekly-return volatility.
Up/down split20/30Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -4.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape33/100

Trend, activity pressure, participation, and risk combine to a 33/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Factors32/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 88; Small Cap Core rank 35 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 15 relevant articles.

HUTCHMED (NASDAQ:HCM) Announces Earnings Results Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026184.0 GBP8.2%194.7 GBP243.3 GBP-0.00-18.80280.7KOff
31 Jul 2026170.0 GBP2.4%195.8 GBP243.5 GBP-0.53-25.29135.2KOff
24 Jul 2026166.0 GBP-5.1%197.0 GBP244.1 GBP-0.73-27.0594.9KOff
17 Jul 2026175.0 GBP6.1%198.0 GBP244.5 GBP-0.95-23.0167.1KOff
10 Jul 2026165.0 GBP-7.3%198.8 GBP244.7 GBP-1.19-27.49125.2KOff
3 Jul 2026178.0 GBP11.2%200.1 GBP244.9 GBP-1.32-23.8335.8KOff
26 Jun 2026160.0 GBP0.9%201.2 GBP245.0 GBP-1.53-30.988.8KOff
19 Jun 2026158.5 GBP-3.9%203.3 GBP245.2 GBP-1.52-31.2510.8KOff
12 Jun 2026165.0 GBP2.2%205.3 GBP245.3 GBP-1.52-29.7634.0KOff
5 Jun 2026161.5 GBP-7.7%207.4 GBP245.6 GBP-1.45-31.31126.6KOff
29 May 2026175.0 GBP-1.5%209.8 GBP245.8 GBP-1.40-26.48153.7KOff
22 May 2026177.8 GBP-3.9%211.3 GBP246.0 GBP-1.26-26.1580.1KOff
15 May 2026185.0 GBP-5.1%213.0 GBP246.2 GBP-1.08-21.55185.7KOff
8 May 2026195.0 GBP0.0%214.2 GBP246.3 GBP-0.53-17.99104.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context